In brief
- On July 14, 2026, the U.S. FDA published the final version of its guidance for designing clinical trials with psychedelic drugs, updating the June 2023 draft.
- The agency has also scheduled a public hearing for September 14 to gather input on the future therapeutic use of these substances in medical settings.
- Psilocybin is among the programs described: the COMP360 compound from the British firm Compass Pathways holds a priority review voucher, and the manufacturer expects to file for U.S. approval before the end of 2026.
The U.S. Food and Drug Administration (FDA) has published the final version of its guidance on the design of clinical trials for psychedelic drugs, a generally nonbinding recommendation document for this class of substances. The publication coincides with the announcement of a public hearing in September and is part of a regulatory acceleration process that is already benefiting two psilocybin research programs.
The challenge of blinding, at the heart of the guidance
One of the greatest scientific hurdles in psychedelic research is what is known as “functional unblinding.” In a placebo-controlled trial, both the patient and the therapist can easily guess who received the active drug because its effects—intense alterations in perception and states of consciousness—are difficult to mask. This compromises the double-blind design typically required by the FDA for drug approval, as the expectations of both the patient and the evaluator can inflate perceived results. The final guidance provides the industry with more concrete criteria to address this issue, in addition to recommendations on long-term follow-up, the integration of psychotherapy into treatment, and safety monitoring in potentially vulnerable populations.
Psilocybin leads the regulatory race
The new framework follows an executive order signed last April by President Donald Trump to accelerate the research, review, and approval of psychedelic drugs for therapeutic purposes. Days later, the FDA granted “national priority vouchers”—capable of compressing a review that typically takes ten to twelve months down to just one or two—to three programs: psilocybin for treatment-resistant depression, psilocybin for major depressive disorder, and methylone, a compound with effects similar to MDMA, for post-traumatic stress disorder. Psilocybin had already received “breakthrough therapy” designation from the FDA for both depressive indications.
One program is COMP360, the synthetic psilocybin developed by Compass Pathways. In February 2026, the company announced that its two phase 3 trials—COMP005, with 258 participants, and COMP006, with 581—had met their primary endpoints: COMP005 tested one dose and COMP006 two 25 mg doses three weeks apart, reducing depressive symptoms, as measured by the MADRS scale, significantly more than the placebo or a low-dose comparator (differences of 3.6 and 3.8 points, with p<0.001, at six weeks). Respectively, 25% and 39% of the 25 mg arms achieved the company-defined MADRS reduction of at least 25%. In its February release, the company stated a Q4 2026 NDA submission goal; that plan guarantees neither filing, approval nor a decision date.
What this implies
The FDA’s accelerated timeline does not mean that approval is guaranteed or imminent for all compounds. The July notice scheduled a hearing for September 14, 2026, whose outcomes are not evaluated here, and the director of the National Institutes of Health (NIH), Jay Bhattacharya, has warned that “there is still much to learn about the long-term benefits and risks, including the potential for misuse.” It is also worth noting that the Compass Pathways trials recorded serious adverse events—11 events in eight participants (5%) in the COMP005 25 mg arm and six in six participants (2%) in COMP006, across different observation phases; the below-1% figure referred specifically to serious suicidal ideation—and that the differences on the MADRS scale, while statistically significant, are moderate in absolute terms. No European body, including the AEMPS, has yet approved psilocybin as a medicine; if U.S. approval is confirmed, the treatment would continue to be administered under medical supervision in a clinical setting, never autonomously.
Sources
- FDA / HHS. Considerations for Potential Future Therapeutic Use of Psychedelic Drugs; Public Hearing; Request for Comments. Federal Register, July 14, 2026.
- Compass Pathways. Successfully Achieves Primary Endpoint in Second Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression. Compass Pathways Investor Relations, February 17, 2026.
Educational content written from a harm reduction perspective and with respect for individual freedom. It is not a substitute for advice from a healthcare professional and is not intended to encourage or condemn any drug use.
